Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Novartis updates Zortress label; advances Fanconi anemia and IgAN trialsSep 16Weekly roundup, 4 itemsatrasentaneltrombopag
Novartis: TOUR006 Phase 2 results posted in CKD; eltrombopag pediatric PK study also reports outAug 12Weekly roundup, 5 itemseltrombopagNovartis
FDA approves Teva's generic eltrombopag olamine tablets in three strengthsJul 13Regulatory decisioneltrombopagTeva Pharmaceutical Industries Ltd